ALL subtypes and risk groups by treatment arm and in the combined cohort
| n (%) . | InO n = 43 . | SC n = 48 . | Combined n = 91 . | Leukemic subtype–based classification of risk group∗ . |
|---|---|---|---|---|
| BCR::ABL1+ | 6 (14.0) | 7 (14.6) | 13 (14.3)† | High-risk BCR::ABL1+ |
| BCR::ABL1 like | 7 (16.3) | 5 (10.2) | 12 (13.2) | High-risk BCR::ABL1− |
| Low hypodiploidy | 3 (7.0) | 8 (16.7) | 11 (12.1) | High-risk BCR::ABL1− |
| KMT2A | 2 (4.7) | 6 (12.5) | 8 (8.8) | High-risk BCR::ABL1− |
| DUX4 | 3 (7.0) | 2 (4.2) | 5 (5.5) | Standard to intermediate risk |
| Hyperdiploid‡ | 3 (7.0) | 0 | 3 (3.3) | Standard to intermediate risk |
| CDX2/UBTF | 2 (4.7) | 1 (2.1) | 3 (3.3) | Undetermined risk |
| B-other | 1 (2.3) | 1 (2.1) | 2 (2.2) | Undetermined risk |
| MEF2D | 1 (2.3) | 1 (2.1) | 2 (2.2) | Standard to intermediate risk |
| PAX5alt | 0 | 2 (4.2) | 2 (2.2) | Standard to intermediate risk |
| TCF3::PBX1 | 1 (2.3) | 1 (2.1) | 2 (2.2) | Standard to intermediate risk |
| ZEB2/CEBP | 0 | 2 (4.2) | 2 (2.2) | Undetermined risk |
| ZNF384 | 1 (2.3) | 0 | 1 (1.1) | Standard to intermediate risk |
| Low-blast§ | 13 (30.2) | 12 (24.5) | 25 (27.5) | Low blast |
| n (%) . | InO n = 43 . | SC n = 48 . | Combined n = 91 . | Leukemic subtype–based classification of risk group∗ . |
|---|---|---|---|---|
| BCR::ABL1+ | 6 (14.0) | 7 (14.6) | 13 (14.3)† | High-risk BCR::ABL1+ |
| BCR::ABL1 like | 7 (16.3) | 5 (10.2) | 12 (13.2) | High-risk BCR::ABL1− |
| Low hypodiploidy | 3 (7.0) | 8 (16.7) | 11 (12.1) | High-risk BCR::ABL1− |
| KMT2A | 2 (4.7) | 6 (12.5) | 8 (8.8) | High-risk BCR::ABL1− |
| DUX4 | 3 (7.0) | 2 (4.2) | 5 (5.5) | Standard to intermediate risk |
| Hyperdiploid‡ | 3 (7.0) | 0 | 3 (3.3) | Standard to intermediate risk |
| CDX2/UBTF | 2 (4.7) | 1 (2.1) | 3 (3.3) | Undetermined risk |
| B-other | 1 (2.3) | 1 (2.1) | 2 (2.2) | Undetermined risk |
| MEF2D | 1 (2.3) | 1 (2.1) | 2 (2.2) | Standard to intermediate risk |
| PAX5alt | 0 | 2 (4.2) | 2 (2.2) | Standard to intermediate risk |
| TCF3::PBX1 | 1 (2.3) | 1 (2.1) | 2 (2.2) | Standard to intermediate risk |
| ZEB2/CEBP | 0 | 2 (4.2) | 2 (2.2) | Undetermined risk |
| ZNF384 | 1 (2.3) | 0 | 1 (1.1) | Standard to intermediate risk |
| Low-blast§ | 13 (30.2) | 12 (24.5) | 25 (27.5) | Low blast |
B-other, cases without an identified subtype-defining driver genetic alteration.
Paietta et al2.
ABL1 T315I mutations were reported in 9 patients (InO, n = 3; SC, n = 6).
Confirmed by RNA-sequencing copy number variation (analysis) for absence of fusions and absence of CREBBP mutations.
Low-blast: blasts of <30%; subtype undetermined.